Atara Biotherapeutics Inc.

Atara Biotherapeutics Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapies for patients with severe and life-threatening diseases.

Atara Biotherapeutics Inc.

Range dropdown markets


After hours

EDT Delayed quote

$ 2.8600

0.00 0.00%

After Hours Volume: 30.26K

Close Chg Chg
$2.8600 -0.0100 -0.35%

Volume: 1.12M 65-Day Average: 1.35M

83% vs Average 2.7700 Days Range 2.9700 to 2.6600 52-Week Range 10.0100

Key Data

% of Float Shorted 15.45%
Average Volume 1.35M


5 Days


1 Month


3 Months




1 Year


Other News Press Releases

89bio (ETNB), Up 25% on Upbeat data from Mid-Stage NASH study

Mar. ET on

Sanofi's (SNY), Dupixent Meets Pivotal COPD Study Goal

Mar. ET on

Karuna's (KRTX), KarXT Reaches Primary Goal in Schizophrenia Research

Mar. ET on

Esperion (ESPR), Drops 54% During Milestone Payment Row

Mar. ET on

Merck's (MRK), Co-formulation Therapy Failed Lung Cancer Study

Mar. ET on

Atara Biotherapeutics's Return on Capital Employed

February 10, 2023, 9:50 a.m. ET on

Analysts have Conflicting Views on these Healthcare Companies: Galapagos, Atara Biotherapeutics and Teva Pharmaceutical (TEVA).

February 9, 2023, 7:40 a.m. ET at

Mizuho Securities Maintains their Buy Rating for Atara Biotherapeutics.

Twelve Health Care Stocks Move In Wednesday's After Market Session

February 8, 2023, 4:31 p.m. ET on

Why Bed Bath & Beyond fell nearly 30%; Here are 20 stocks that are moving premarket

Mizuho Securities Maintains their Buy Rating for Atara Biotherapeutics.

Benzinga's Top Rated Ratings Upgrades and Downgrades for January 5, 2023

Li Auto, XPeng and Nio Move Higher in Today's Premarket Session

Three Under-the-Radar Biotech Stocks You Should Buy in 2022

Dec. 24, 2022, 10:07 a.m. ET on Motley Fool

Atara (NASDAQ,ATRA) to Receive $31 million to Propagate Epstein-Barr Therapy

Dec. 21, 2022, 2:45 a.m. ET on

Twelve Health Care Stocks Move In Tuesday's Premarket Session

Dec. 20, 2022, 8:07 a.m. ET on

Today's Top Pre-Market Stock Movers: Ten Top Gainers and 10 Top Losers on Tuesday

Atara Biotherapeutics Inc.

Atara Biotherapeutics, Inc., an allogeneic T cell immunotherapy company, develops transformative therapies for patients suffering from serious diseases such as solid tumors, hematologic and autoimmune cancers. It also provides off-the-shelf treatment to patients with high unmet needs. Tab-cel is part of the company's product portfolio. Isaac E. Ciechanover founded the company on August 22, 2012. It is located in Thousand Oaks (CA).